Cargando…
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety...
Autores principales: | Han, Sue, Liu, Yang, Cai, Sabrina J., Qian, Mingyu, Ding, Jianyi, Larion, Mioara, Gilbert, Mark R., Yang, Chunzhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250901/ https://www.ncbi.nlm.nih.gov/pubmed/32291392 http://dx.doi.org/10.1038/s41416-020-0814-x |
Ejemplares similares
-
DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021) -
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020) -
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
por: Liu, Yang, et al.
Publicado: (2020) -
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
por: Dimitrov, Lilia, et al.
Publicado: (2015) -
Sphingolipid Pathway as a Source of Vulnerability in IDH1(mut) Glioma
por: Dowdy, Tyrone, et al.
Publicado: (2020)